84
Participants
Start Date
September 30, 2005
Primary Completion Date
March 31, 2009
Study Completion Date
March 31, 2009
carboplatin
AUC of 6 mg\*min/mL via IV infusion every 21 days for 4 cycles as per institutional practices.
paclitaxel
175-225 mg/m2 via IV infusion every 21 days for 4 cycles as per institutional practices.
sunitinib
50 mg orally daily for 4 weeks followed by 2 weeks off treatment up to 1 year (after completing 1 year of treatment, pts deriving clinical benefit may continue to receive sunitinib in a separate continuation protocol).
Pfizer Investigational Site, Caen
Pfizer Investigational Site, Hershey
Pfizer Investigational Site, Newark
Pfizer Investigational Site, Newark
Pfizer Investigational Site, Wilmington
Pfizer Investigational Site, Gallatin
Pfizer Investigational Site, Franklin
Pfizer Investigational Site, Hermitage
Pfizer Investigational Site, Lebanon
Pfizer Investigational Site, Murfreesboro
Pfizer Investigational Site, Smyrna
Pfizer Investigational Site, Nashville
Pfizer Investigational Site, Nashville
Pfizer Investigational Site, Nashville
Pfizer Investigational Site, Nashville
Pfizer Investigational Site, Shelbyville
Pfizer Investigational Site, Louisville
Pfizer Investigational Site, Louisville
Pfizer Investigational Site, Louisville
Pfizer Investigational Site, Jeffersonville
Pfizer Investigational Site, Maywood
Pfizer Investigational Site, Burleson
Pfizer Investigational Site, Cleburne
Pfizer Investigational Site, Mineral Wells
Pfizer Investigational Site, Weatherford
Pfizer Investigational Site, Fort Worth
Pfizer Investigational Site, Los Angeles
Pfizer Investigational Site, Villejuif
Pfizer Investigational Site, Nashville
Pfizer Investigational Site, Vancouver
Pfizer Investigational Site, Montreal
Lead Sponsor
Pfizer
INDUSTRY